Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Grazoprevir

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Grazoprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP11

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Grazoprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Grazoprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)

    NCT02601573 · start 2016-01-05

    Registered record
    Registry ID
    NCT02601573
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir; Elbasvir; Ribavirin; Sofosbuvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-01-05
    Completion
    2017-01-06
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir; Elbasvir; Ribavirin; Sofosbuvir
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)

    NCT02613403 · start 2015-12-10

    Registered record
    Registry ID
    NCT02613403
    Conditions
    Hepatitis; Hepatitis C; Digestive System Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Liver Diseases; RNA Virus Infections; Virus Diseases
    Interventions
    MK-3682B; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-12-10
    Completion
    2017-03-27
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis; Hepatitis C; Digestive System Diseases; Flaviviridae Infections +4 more
    InterventionMK-3682B; Ribavirin
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

    NCT02358044 · start 2015-02-27

    Registered record
    Registry ID
    NCT02358044
    Conditions
    Hepatitis C
    Interventions
    Sofosbuvir; PegIntron; Ribavirin; Grazoprevir/Elbasvir (100 mg/50 mg) FDC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02-27
    Completion
    2016-02-16
    Enrolment
    257

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionSofosbuvir; PegIntron; Ribavirin; Grazoprevir/Elbasvir (100 mg/50 mg) FDC
    PhasePhase 3
    Registry statusCompleted

  • eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

    NCT04047680 · start 2015-02

    Registered record
    Registry ID
    NCT04047680
    Conditions
    Hepatitis C; Renal Disease; Viral Hepatitis C
    Interventions
    Sofosbuvir / Velpatasvir Oral Tablet; Sofosbuvir and Ledipasvir; Sofosbuvir Tablets; Ombitasvir/paritaprevir/ritonavir; Elbasvir / Grazoprevir Oral Tablet; Glecaprevir and Pibrentasvir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-02
    Completion
    2019-06
    Enrolment
    441

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Renal Disease; Viral Hepatitis C
    InterventionSofosbuvir / Velpatasvir Oral Tablet; Sofosbuvir and Ledipasvir; Sofosbuvir Tablets; Ombitasvir/paritaprevir/ritonavir +2 more
    PhaseNot recorded
    Registry statusCompleted

  • Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

    NCT02251990 · start 2015-01-28

    Registered record
    Registry ID
    NCT02251990
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir/Elbasvir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-01-28
    Completion
    2017-04-10
    Enrolment
    489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir/Elbasvir; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

    NCT02332707 · start 2015-01-22

    Registered record
    Registry ID
    NCT02332707
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir; Uprifosbuvir; Elbasvir; Ruzasvir; Uprifosbuvir (+) Grazoprevir (+) Ruzasvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01-22
    Completion
    2016-12-06
    Enrolment
    443

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir; Uprifosbuvir; Elbasvir; Ruzasvir +2 more
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

    NCT02333292 · start 2014-12

    Registered record
    Registry ID
    NCT02333292
    Conditions
    Chronic Hepatitis C Infection
    Interventions
    Telaprevir; Boceprevir; Sofosbuvir; Simeprevir; Daclatasvir; Ledipasvir; ritonavir-boosted Paritaprevir/ Ombitasvir; Dasabuvir; Velpatasvir; Elbasvir; Grazoprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-12
    Completion
    2017-06-30
    Enrolment
    1,128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Infection
    InterventionTelaprevir; Boceprevir; Sofosbuvir; Simeprevir +7 more
    PhaseNot recorded
    Registry statusCompleted

  • Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)

    NCT02252016 · start 2014-10-22

    Registered record
    Registry ID
    NCT02252016
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir + Elbasvir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10-22
    Completion
    2016-06-14
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir + Elbasvir; Placebo
    PhasePhase 3
    Registry statusCompleted

  • An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)

    NCT02105688 · start 2014-09-02

    Registered record
    Registry ID
    NCT02105688
    Conditions
    Chronic Hepatitis C
    Interventions
    Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A); Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-09-02
    Completion
    2018-12-04
    Enrolment
    301

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionGrazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A); Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet
    PhasePhase 3
    Registry statusCompleted

  • Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

    NCT02105701 · start 2014-06-05

    Registered record
    Registry ID
    NCT02105701
    Conditions
    Hepatitis C Infection
    Interventions
    Grazoprevir + Elbasvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06-05
    Completion
    2015-06-19
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Infection
    InterventionGrazoprevir + Elbasvir; Ribavirin
    PhasePhase 3
    Registry statusCompleted

  • Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

    NCT02105454 · start 2014-05-23

    Registered record
    Registry ID
    NCT02105454
    Conditions
    Hepatitis C Virus
    Interventions
    Grazoprevir (GZR); Elbasvir (EBR); Ribavirin (RBV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05-23
    Completion
    2015-05-04
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus
    InterventionGrazoprevir (GZR); Elbasvir (EBR); Ribavirin (RBV)
    PhasePhase 2
    Registry statusCompleted

  • Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

    NCT02115321 · start 2014-05-09

    Registered record
    Registry ID
    NCT02115321
    Conditions
    Chronic Hepatitis C
    Interventions
    Grazoprevir; Elbasvir; MK-5172A
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-05-09
    Completion
    2015-06-16
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionGrazoprevir; Elbasvir; MK-5172A
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

    NCT02092350 · start 2014-03-17

    Registered record
    Registry ID
    NCT02092350
    Conditions
    Hepatitis C Virus
    Interventions
    Grazoprevir; Elbasvir; Placebo to Grazoprevir; Placebo to Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-03-17
    Completion
    2015-09-02
    Enrolment
    237

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus
    InterventionGrazoprevir; Elbasvir; Placebo to Grazoprevir; Placebo to Elbasvir
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)

    NCT01537900 · start 2013-10-01

    Registered record
    Registry ID
    NCT01537900
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10-01
    Completion
    2014-07-31
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

    NCT01932762 · start 2013-10-01

    Registered record
    Registry ID
    NCT01932762
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir; Elbasvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10-01
    Completion
    2014-12-04
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir; Elbasvir; Ribavirin
    PhasePhase 2
    Registry statusCompleted